Current Report Filing (8-k)
09 June 2016 - 7:23AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
June 8, 2016
LION BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in
Charter)
Nevada
(State of Incorporation)
|
000-53127
|
|
75-3254381
|
Commission File Number
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
112 W. 34th Street, 17th Floor
|
|
|
New York, NY
|
|
10120
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(212) 946-4856
|
(Registrant’s Telephone Number, Including Area Code)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
On June 8, 2016, Lion Biotechnologies, Inc.
issued a press release announcing that its Board of Directors has determined to reschedule the company's 2016 Annual Meeting of
Stockholders, which was originally scheduled to be held on Friday, June 10, 2016. A copy of the press release is attached to this
Report as Exhibit 99.1.
|
Item 9.01
|
Financial Statements And Exhibits
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release issued by Lion Biotechnologies, Inc. on June 8, 2016
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: June 8, 2016
|
LION BIOTECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ MOLLY HENDERSON
|
|
|
|
|
Molly Henderson, Chief Financial Officer
|
|
|
|
|
|
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024